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Abstract
Background and Objective The real prevalence of congenital Chagas disease is undefined because of difficulties in the detec-
tion of Trypanosoma cruzi by microscopic examination. The aim of this study was to determine the diagnostic accuracy of 
two molecular diagnostic tools, qPCR and LAMP, in the diagnosis of congenital Chagas disease in a clinical setting.
Methods To this end, we conducted a prospective cohort study in a tertiary care center, of infants under 9 months of age, born 
in Buenos Aires to women with Chagas disease. Blood samples were collected for microscopic examination and molecular 
diagnosis at baseline. If negative, infants were followed up until 9 months of age to determine a final diagnosis by serology. 
In-house qPCR and LAMP previously validated were challenged as index tests.
Results A total of 154 participants were potentially eligible, 120 of whom were enrolled. Finally, 102 (66.2%) of them 
fulfilled the follow-up. The diagnosis of congenital Chagas disease was confirmed in 13 infants and excluded in 89. Both 
the sensitivity and specificity of the qPCR were 100.0% (95% confidence interval 75.3–100.0 and 95% confidence interval 
95.9–100.0, respectively), whereas the sensitivity and specificity of LAMP were 69.2% (95% confidence interval 38.6–90.9) 
and 100% (95% confidence interval 95.9–100.0), respectively.
Conclusions The qPCR agreed with the current diagnostic algorithm, and was a reliable and sensitive tool to detect congenital 
Chagas disease earlier, providing an appropriate and timely identification of infected infants requiring treatment. LAMP was 
able to detect congenital Chagas disease in infected infants by naked-eye visualization in accordance with a microscopic 
examination. The advantages of molecular diagnostic tools should be taken into account by the health system to improve 
congenital Chagas disease diagnosis.
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1 Introduction
Trypanosoma cruzi is the etiological agent of Chagas dis-
ease. In this zoonotic disease, the parasite is transmitted by 
different routes, among which congenital transmission is the 
most important both in endemic areas where vector popu-
lations are under control and in non-endemic areas [1]. In 
endemic countries, it is estimated that between 8000 and 
15,000 T. cruzi-infected infants are born to infected moth-
ers every year. Early diagnosis of congenital Chagas disease 
(CCD) is considered a cost-effective strategy as, in contrast 
to the disease in adults, the cure rate in infants under 1 year 
of age is almost 100% and tolerance to treatment is accept-
able [2, 3]. However, current diagnosis of CCD in infants is 
complex and requires an algorithm based on various tests 
performed during an 8- to 10-month follow-up [1]. Parasi-
tological diagnosis in infants involves concentration tech-
niques via centrifugation using capillary or microtubes for 
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Key Points 
Current diagnosis of congenital Chagas disease is com-
plex and requires an algorithm based on various tests 
performed during an 8- to 10-month follow-up. A late 
diagnosis results in missed opportunities for the treat-
ment of infected infants.
Although several studies have shown the high sensitiv-
ity of PCR in congenital Chagas disease diagnosis, in 
most Latin American countries, this tool had not been 
validated in routine screening and its implementation is 
still limited. There is a need to obtain more evidence in 
order to modify current practice.
Our study evidenced moderate and high overall accu-
racy of LAMP and qPCR, respectively. Considering the 
advantages and limitations of these molecular diagnostic 
tools, these should be taken into account by the health 
system to improve early diagnosis and treatment of con-
genital Chagas disease.
for T. cruzi detection [14–16]. Before implementation into 
routine clinical practice and incorporation into guidelines, 
every new diagnostic assay should go through a lengthy vali-
dation process. Although both T. cruzi qPCR and LAMP 
have been analytically validated [14, 17], they have not yet 
been clinically validated to assess their clinical utility. Thus, 
the aim of this study was to determine the diagnostic accu-
racy of qPCR and LAMP previously analytically validated in 
the diagnosis of CCD in a clinical setting, using the current 
diagnostic algorithm as the diagnostic reference standard. 
In vitro diagnostics assays are not commercially available 
for qPCR or LAMP. Therefore, two in-house assays whose 
validations had been published and could be performed in 
the clinical setting were selected: a PCR assay targeting the 
T. cruzi nuclear satellite and a LAMP assay targeting 18S 
rRNA genes.
2  Materials and Methods
2.1  Study Population
The samples analyzed were obtained in the context of a pro-
spective cohort study conducted in infants. A total of 154 
potentially eligible infants born to T. cruzi-infected moth-
ers who attended the Parasitological and Chagas Service of 
the Hospital de Niños “Ricardo Gutiérrez”, Buenos Aires, 
Argentina, for a CCD diagnosis between July 2012 and 
December 2015 were consecutively recruited for this study 
following Good Clinical Practices. The accuracy of both 
qPCR and LAMP was evaluated according to the Standards 
for the Reporting of Diagnostic Accuracy Studies (STARD) 
statement [18].
Subjects meeting the following criteria were considered 
for inclusion: infants aged under 9 months, T. cruzi maternal 
serology reactive by two serological tests, and at least one 
blood sample available for molecular diagnosis. Exclusion 
criteria were: mother or infants who had received previous 
treatment for Chagas disease; infants born in or who had 
traveled to an area endemic for Chagas disease.
2.2  Reference Standard by the Current CCD 
Diagnostic Algorithm
All infants recruited were screened for T. cruzi infection 
according to the official guidelines [19]. Briefly, infection 
in infants under 9 months of age was assessed by ME per-
formed by a trained biochemist with 10 years of experience 
using the microhematocrit method [20]. In the case of a neg-
ative ME result, infants were followed up every 3 months 
until 9 months of age by ME. Infection of T. cruzi in infants 
aged older than 9 months was confirmed or discarded by 
the detection of parasites from the buffy coat by microscopic 
examination (ME) [1, 4, 5]. Although these techniques con-
centrate parasites, they have limited clinical sensitivity 
because of multiple factors, including the parasitic loads and 
technical issues such as operator dependence [6]. Addition-
ally, no quality-control system may be available for ME [7]. 
Therefore, CCD diagnosis in infants relies on serological 
methods at 8–10 months, once maternal antibodies become 
undetectable [1].
In endemic countries where the primary healthcare sys-
tem is weak and the vulnerable population does not have 
access to the healthcare system, the above-mentioned diag-
nostic algorithm has been difficult to implement. In Argen-
tina, the available data show deficiencies in the follow-up 
of infants and CCD notification, and the real incidence and 
clinical burden of this disease are unknown [8]. In fact, the 
Pan American Health Organization recognizes that CCD 
may be underestimated because maternal and infant health-
care centers do not routinely screen mothers and/or infants, 
and thus recommends actively exploring opportunities to 
diagnose and cure ≥ 90% of infants with CCD [9].
In this context, an alternative or complement to the cur-
rent CCD diagnostic algorithm could be parasite DNA 
detection using molecular diagnostic tools, but their imple-
mentation in endemic regions remains limited to reference 
centers [10]. Over 20 years, the PCR technique has been pre-
sented as a promising tool for sensitive and specific detection 
of T. cruzi parasites [11–13]. Furthermore, isothermal DNA 
amplification (LAMP), which requires less infrastructure, 
has been reported as a possible molecular diagnostic tool 
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two serological tests currently used in Argentina: Chagatest 
ELISA recombinante v.3.0 (Wiener Lab, Rosario, Argen-
tina) and indirect hemagglutination Chagatest-HAI (Wiener 
Lab) (Fig. 1). Because at least two positive serological tests 
are necessary to consider a patient to be infected, as rec-
ommended by the World Health Organization and the Pan 
American Health Organization [21], in cases of inconclu-
sive serological results, a passive particle agglutination test 
(Bayer, Buenos Aires, Argentina) was performed. All three 
assays are validated commercial tests widely used in clinical 
settings. In short, infants were considered infected when an 
ME before 9 months or two serological tests over 9 months 
were positive, whereas they were considered not infected 
when both ME and two serological tests over 9 months were 
negative. This algorithm was the reference standard.
2.3  Sample Collection for Index Tests
Venous blood samples for molecular diagnosis were 
obtained by direct puncture of the antecubital area of the arm 
at baseline (T1), when infants were recruited, and at the end 
of the follow-up (T2), at 9 months of age (Fig. 1). Samples 
were preserved as previously described [12]. Depending on 
the likelihood of being able to obtain a certain blood volume 
in each procedure, we chose to collect 0.5, 1, or 2 mL of 
blood, which was preserved in a tube containing the same 
volume of guanidine 6M-EDTA 0.2 M buffer (GE buffer) 
and, after 48–72 h, samples were heated at 100 °C for 5, 10, 
or 15 min respectively and stored at 4 °C until processing. 
Samples at T1 were then analyzed by the two index tests 
chosen: qPCR and LAMP to assess the diagnostic accuracy. 
Samples at T2 were then analyzed by qPCR to establish the 
parasitic load in those cases with positive results. Laboratory 
technicians ascertaining the results of the qPCR and LAMP 
were blinded to the results of the reference standard.
2.4  DNA Extraction
Samples were processed using the High Pure PCR Tem-
plate Preparation Kit (Roche Diagnostics Corp., Indianapo-
lis, IN, USA), according to the manufacturer’s instructions 
with slight modifications. Namely, 5 μL of internal positive 
control (IPC, previously described by Duffy et al. [17]) was 
added to 300 μL of each sample and this mix was processed 
[22]. Each round of DNA extraction was performed using 
ten blood samples: eight from patients, one from a negative 
control for T. cruzi infection, and one from a positive extrac-
tion control (see below). After extraction, DNA was stored 
at − 20 °C until use in the qPCR or LAMP assays.
2.5  PCR Reaction
A multiplex qPCR assay able to quantify the T. cruzi nuclear 
satellite and IPC DNA in a single-tube reaction previously 
analytically validated was implemented [22]. The qPCR 
reactions were carried out with 5 μL of eluted DNA, using 
FastStart Universal Probe Master Mix (Roche Diagnostics 
GmbHCorp, Mannheim, Germany) in a final volume of 20 
μL. The amplifications were carried out using 750 nM of 
the cruzi1 and cruzi2 primers, 50 nM of the cruzi3 probe, 
100 nM of the IACTqFw and IACTqRv primers, and 50 nM 
of the IACTq probe. The TaqMan MGB cruzi3 and IACTq 
probes were labeled with FAM and VIC dye, respectively. 
The cycling conditions were as follows: 10 min at 95 °C, 
and 40 cycles of 15 s at 95 °C, followed by 1 min at 58 °C. 
The amplifications were carried out in a StepOne Real Time 
PCR System (Applied Biosystems, Foster City, CA, USA). 
Two negative controls (water and DNA from non-infected 
human samples) and two positive amplification controls (5 
and 50 fg of DNA purified from T. cruzi trypomastigotes per 
tube) were included in every round. To analyze the results, 
the threshold was set at 0.02 and 0.01 for T. cruzi and IPC, 
respectively. Samples that yielded negative IPC results were 
discarded. Clinical samples were considered positive when 
the fluorescent signals crossed the threshold.
2.6  Spiked Blood Samples
Blood samples from non-T. cruzi-infected individuals were 
mixed with the same volume of GE buffer and processed as 
clinical samples. A pool of negative samples were spiked 
with cultured T. cruzi trypomastigotes, VD strain. Try-
pomastigotes were obtained from the supernatants of Vero 
cell cultures harvested between days 5 and 9 post-infection 
Fig. 1  Sample collection 
diagram during our prospec-
tive cohort study. Baseline, at 
the time of recruitment; End of 
follow-up, at 9 months of age
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[23]. This strain corresponds to the discrete typing unit 
(DTU) TcVI and was isolated from a patient with CCD 
assisted in our service [24]. TcVI was chosen because 
TcII/V/VI populations have been identified in most patients 
residing in Argentina [25].
2.7  Standard Curves
To build the standard curve for the quantification of parasitic 
loads, DNA from spiked samples that contained  106 try-
pomastigotes/mL was extracted as previously described, fol-
lowed by serial dilutions to obtain concentrations of 5.105 to 
0.5 parasite equivalents per milliliter of blood (par. eq./mL). 
As diluent, the DNA extracted from a blood sample of a non-
infected individual was used. Each dilution was amplified by 
qPCR in triplicate. To obtain the absolute quantification of 
parasitic loads from clinical samples, results were interpo-
lated on the standard curve by the StepOne Software v2.3.
2.8  Quality Assessment of qPCR
To verify the analytical performance previously reported 
[22], a replicate test was performed to verify the reported 
limit of detection (the lowest parasitic load that gives 95% of 
positive results). DNA from spiked samples that contained 
0.5, 2, and 5 par. eq./mL was extracted and amplified for 10 
consecutive days (two replicates for each dilution) in the 
same manner as reported for the clinical samples.
To ensure the quality of the assay over time, a pool of 
blood samples from seronegative patients was spiked with 
cultured trypomastigotes to reach a concentration of 5 par. 
eq./mL load. Aliquots were stored at 4 °C to perform a repli-
cate test for each DNA extraction round (positive extraction 
control). Ct results obtained by qPCR were plotted using 
quality-control charts.
2.9  LAMP Reaction
We have previously validated a LAMP reaction targeted to 
the 18S rRNA genes [14]. Briefly, DNA samples (5 μL) were 
subjected to amplification in reaction mixtures containing 
40 pmol of the FIP and BIP primers, 20 pmol of the LF and 
LB primers, 5 pmol of the F3 and B3 primers, 1 μL (8 units) 
of Bst DNA polymerase (New England Biolabs, Ipswich, 
MA, USA), 1X reaction buffer (which is composed of 20 
mM of Tris-HCl, 10 mM of KCl, 8 mM of  MgSO4, 10 mM 
of [NH4]  2SO4, 0.1% Tween-20), 1.4 mM of each dNTP, 
an additional 8 mM of  MgSO4, and 0.5 M of betaine. The 
reaction was performed at 55 °C for 60 min, using a heat 
block  (Labnet®) for amplification. Two negative controls 
(water and DNA from non-infected human samples) and a 
positive amplification control (DNA purified from known 
quantities of T. cruzi trypomastigotes) were included in 
every round. The product was analyzed by visual inspection 
after the addition of 2 μL of the 1000 × concentrated fluores-
cent dye,  SYBR® Green (S7563) [Invitrogen, Eugene, OR, 
USA]. LAMP results are qualitative and therefore expressed 
as positive or negative. An immediate change to green fluo-
rescence indicated a positive result, whereas an orange color 
indicated a negative result.
2.10  Ethics
This protocol was reviewed and approved by the Research 
and Teaching and Bioethics Committees from “Ricardo 
Gutiérrez” Children’s Hospital (CEI No. 10.57). Written 
informed consent to participate was obtained from each 
patient’s legal representative. All samples were decoded and 
identified before they were provided for research purposes. 
Infected patients were treated with benznidazole (100-mg 
tablets,  Abarax®; Laboratorio Elea, Buenos Aires, Argen-
tina) at 5–8 mg/kg body weight, as soon as the diagnosis 
was confirmed, divided in two daily doses for 60 days [2].
2.11  Data Analysis
Results were analyzed using Microsoft Excel and Graph-
Pad Prism software 6.0. Confidence intervals (CIs) were 
calculated and the p value was considered significant at a 
value of at least 0.05. Data are expressed as mean ± standard 
deviation with a 95% CI. To evaluate the diagnosis accuracy 
of the two assays, we calculated sensitivity and specificity, 
likelihood ratio, and positive and negative predictive values 
(https:// www. medca lc. org/ calc/ diagn ostic_ test. php).
3  Results
3.1  Populations and Samples
A total of 154 infants were referred to our center for CCD 
diagnosis. Eleven out of the 154 (7.1%) infants were 
excluded from the analysis because maternal serology 
was negative or their mother had been previously treated 
(Fig. 2). Then, 143 (92.9%) patients were eligible partici-
pants to be enrolled in the study. Blood samples for molec-
ular diagnosis from 120 out of these 143 (83.9%) patients 
were available for testing. Samples from 23 patients were 
not available either because no samples were collected (n 
= 18) owing to a difficult blood draw or because specimens 
could not be tested because of inadequate storage with the 
GE buffer (n = 5). All patients were tested by ME at least 
once. Finally, 102 out of the 120 patients completed the 
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follow-up until the T2 appointment. Thus, the completion 
rate was 85.0% (Fig. 2).
Regarding the country of origin of the mothers, 80/120 
(66.7%) were from Bolivia, 26/120 (21.7%) from Argen-
tina, and 10/120 (8.3%) from Paraguay. No data of the 
country of origin were available in 4/120 (3.3%) women. 
A total of 12/26 (46.2%) women from Argentina had been 
born in Buenos Aires, a non-endemic region for Chagas 
disease. All infants were born in and remained within the 
urban limits of Buenos Aires, Argentina, an area free of 
vector-borne T. cruzi transmission without risk of vecto-
rial infection. The mean age of infants at enrollment was 
35 days (age range 3–226 days). All patients were asymp-
tomatic, with no cardiac involvement or other Chagas 
disease-associated pathologies, and no comorbidities or 
laboratory abnormalities.
At the end of the study, 13/120 (10.8%, 95% CI 6.4–17.7) 
infants were diagnosed as CCD infected by the reference 
standard algorithm (Fig. 2): 9/13 (69.2%) were detected 
by ME at baseline (Table 1); 1/13 was diagnosed at a sec-
ond appointment, during follow-up, before T2 (ID: 101, 
T1bis; Table 2); and 3/13 (23.1%) were diagnosed by reac-
tive serology at 9.1, 10.6, and 19.2 months (ID: 061, 053, 
and 052 respectively; Table 2). The mean age at diagnosis 
was 4.4 months (standard deviation ± 5.7). A total of 89 
patients showed negative serology at the end of the follow-
up. Final serology was performed at a mean age of 11.1 
months (standard deviation ± 4.5). For the remaining 18/120 
infants, final diagnosis was not available due to loss during 
follow-up (Fig. 2). 
3.2  Quality‑Control Assessment of qPCR
The qPCR yielded a limit of detection of 2 par. eq./mL. 
For quantitative analysis, the reportable range was 5–5 × 
 105 par. eq./mL and the linear regression analysis showed 
an efficiency of 0.953, an R2 of 0.999, and a CV% (5 par. 
eq./mL) of 2.7. The quality-control charts allowed moni-
toring of the quality of the assay over time. Ct values from 
spiked samples that contained 5 par. eq./mL of blood each 
round were plotted and Westgard rule analysis discarded 
the results of only one round during the study.
3.3  Accuracy of the qPCR and LAMP Assays
A total of 176 samples were obtained from 120 patients 
(119 at T1, 55 at T2, and two additional samples [namely 
T1bis and T2bis] at 3.7 and 19.2 months as a second sam-
ple because a negative reference standard but positive 
qPCR had been obtained). All the 176 samples were tested 
by qPCR, 17 of which yielded positive results and 159 of 
which yielded negative results, whereas 121 out of the 
176 samples were tested by LAMP, ten of which yielded 
positive results and 111 of which yielded negative results.
Fig. 2  Flow diagram of infants 
enrolled in the study. Index 
tests: qPCR and LAMP; refer-
ence standard: microscopic 
examination before 9 months of 
age and serology after 9 months. 
MD molecular diagnosis
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For the 102 patients who completed the follow-up, and 
thus the reference standard was available, the diagnosis 
accuracy of the two molecular tools studied and ME was 
calculated taking into account the first sample analyzed. 
Table 1 shows the accuracy assessed as sensitivity, speci-
ficity, predictive values, and likelihood ratio.
All 13 infected patients were positive by qPCR in the 
first sample tested (sensitivity 100%, 95% CI 75.3–100.0, 
Table 1). In one case, the first sample was obtained at T2 
(ID: 053), and the qPCR was also positive. The details 
of the reference standard and index tests results obtained 
from the 13 infected patients during the follow-up are 
Table 1  Diagnostic accuracy of microscopic examination and molecular tools taking into account the first sample analyzed
CI confidence interval, LAMP isothermal assay, LR − likelihood ratio of a negative test, LR + likelihood ratio of a positive test, ME microscopic 
examination by microhematocrit method, NPV negative predictive value, PPV positive predictive value, qPCR real-time PCR, T1 baseline, T2 
after 9 months of age, TN true negative, TP true positive
a 12 samples collected at T1 and 1 sample collected at T2
Detection method TP TN Sensitivity (95% CI) Specificity (95% CI) Likelihood ratio (95% CI) Predictive value (95% CI)
ME 9/13 89/89 69.2% (38.6–90.9) 100.0% (95.9–100.0) LR + >999 PPV = 100.0%
LR − 0.31 (0.14–0.70) NPV = 95.7% (90.8–98.1)
qPCR 13/13a 89/89 100.0% (75.3–100.0) 100.0% (95.9–100.0) LR + >999 PPV = 100.0%
LR − 0.00 NPV = 100.0%
LAMP 9/13a 89/89 69.2% (38.6–90.9) 100.0% (95.9–100.0) LR + >999 PPV = 100.0%
LR − 0.31 (0.14–0.70) NPV = 95.7% (90.8–98.1)
Table 2  Parasitological and serological findings from congenital Chagas disease-infected infants during the follow-up
D days, LAMP isothermal assay, M months, ME microscopic examination, ND not done, Neg no detectable parasites or non-reactive serology as 
appropriate, NQ not quantifiable (<0.5 par. eq./mL), par. eq./mL parasite equivalents per milliliter of blood, Pos detectable or reactive as appro-
priate, qPCR real-time PCR, QPCR quantitative PCR, T1 baseline, T2 after 9 months of age, T1bis and T2bis off-label appointments
a Reference standard, ME at baseline (T1 and T1bis) and serology at 9 months old or more if ME was negative (T2 and T2bis)
Patient ID Appointment Age Reference standard (ME or 
serology)a
Index tests
LAMP qPCR QPCR 
(par. eq./
mL)
015 T1 6 D Pos Pos Pos 706.2
032 T1 5 D Pos Pos Pos 23.6
037 T1 9 D Pos Pos Pos 347.8
042 T1 7.1 M Pos Pos Pos 4718.3
052 T1 39 D Neg Neg Pos NQ
T2 10.5 M Neg ND Pos 73.6
T2bis 19.2 M Pos ND Pos 7.8
053 T1 8 D Neg ND ND ND
T2 10.6 M Pos Pos Pos 2145.3
061 T1 17 D Neg Neg Pos NQ
T2 9.1 M Pos ND Pos 543.1
084 T1 53 D Pos Pos Pos 257.8
091 T1 4 D Pos Pos Pos 2058.3
101 T1 11 D Neg Neg Pos 27.5
T1bis 3.7 M Pos Pos Pos 3392.8
118 T1 29 D Pos Pos Pos 164.7
140 T1 84 D Pos Pos Pos 1698.0
141 T1 44 D Pos Neg Pos 320.0
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shown in Table 2. Three infants with negative ME at base-
line but CCD diagnosed during the follow-up (see above) 
were positive at baseline by qPCR, i.e., earlier than with 
the reference standard (ID: 052, 061, and 101 detected by 
qPCR at 39, 17, and 11 days old, respectively; Table 2). In 
infected patients from whom other samples were available 
during the follow-up, the qPCR remained positive (T1bis, 
T2, and T2bis, Table 2). However, all 89 non-infected 
patients were negative by qPCR in both T1 and T2 sam-
ples (specificity at baseline 100%, 95% CI 95.9–100.0, 
Table 1).
LAMP results obtained in this study were detected by 
naked-eye visualization, as exemplified in Fig. 3. LAMP 
was positive in 9/13 infected patients in the first sample 
tested (sensitivity: 69.2% 95% CI 38.6–90.9) (Table 1). 
Eight out of the 13 infected patients yielded positive 
LAMP results at T1, whereas four of them yielded nega-
tive LAMP results at T1. In one case, the first sample was 
obtained at T2 (ID: 053) and yielded a positive result. One 
of the 13 infected patients was not detectable by LAMP 
at T1, but was positive at T1bis (ID: 101, Table 2) when 
parasitic loads increased. All 89 non-infected patients 
were negative by LAMP (specificity 100.0%, 95% CI 
95.9–100.0).
3.4  Parasitic Loads in Congenitally Infected Patients
Parasitic loads assessed by quantitative qPCR ranged from 
not quantifiable (positive but less than 5 par. eq./mL) to 
4718.3 par. eq./mL, using a standard curve from seron-
egative blood spiked with the VD strain. Parasitic loads 
exhibited a tendency to increase in infants between 3 and 
9 months of age, although there was a very large varia-
tion in values (Fig. 4). Moreover, when prior to treatment 
at least two positive samples were analyzed during the 12 
first months of life, the parasitic loads increased (ID: 052, 
061, and 101, Table 2). Interestingly, parasites could not be 
detected by ME or LAMP in T1 samples with non-quantifi-
able parasitic loads (ID: 052 and 061, Table 2) or in another 
T1 sample with a low parasitic load (27.4 par. eq./mL, ID: 
101, Table 2). However, the T1 sample from patient ID 032 
with 23.6 par. eq./mL showed positive results by both ME 
and LAMP (Table 2). Additionally, LAMP could not detect 
T. cruzi DNA in a sample with a parasitic load of 320.0 par. 
eq./mL (ID: 141, Table 2). However, in one of the patients 
whose second sample (T1bis) showed an increased parasitic 
load, both the ME and LAMP turned to positive (ID: 101, 
Table 2).
4  Discussion
In this prospective study, we report the diagnostic accuracy 
of two molecular tools (a qPCR and a LAMP assay) for the 
diagnosis of CCD in a routine diagnosis setting. Although 
similar studies have been conducted to evaluate the use of 
qPCR in research settings [26, 27], this is the first work to 
validate the implementation of a T. cruzi LAMP assay for 
the diagnosis of CCD. Our study evidenced moderate and 
high overall accuracy of LAMP and qPCR, respectively. The 
Fig. 3  Visualization of LAMP 
results by the naked eye 
obtained in: tubes 1–3: blood 
samples obtained from non-
infected patients; tube 4: blood 
sample from an infected patient 
(ID: 118, Table 2); tube 5: posi-
tive amplification control (VD 
Trypanosoma cruzi stock); tube 
6: negative control
Fig. 4  Comparative analysis of parasitic load in congenital Chagas 
disease-infected infants on the basis of age, obtained by qPCR assay. 
Graphs show median and interquartile range. par. eq./mL parasite 
equivalents per milliliter of blood
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T. cruzi-qPCR proved to be an appropriate tool to anticipate 
the diagnosis and avoid long follow-up periods.
The transmission rate observed was 10.8%, i.e., higher 
than that observed in other epidemiological studies [1]. Nev-
ertheless, it should be noted that patients were referred for 
CCD diagnosis from other centers. This fact may overesti-
mate the transmission rate.
In the metropolitan area of Buenos Aires, most new Cha-
gas disease cases occur by vertical transmission and many 
infections are currently second-generation congenital cases, 
meaning that their mothers were themselves congenital cases 
[28]. In our study, at least 5 out of the 13 infected infants 
were born to women who had never traveled to endemic 
areas. In fact, this should be considered by healthcare teams 
to eliminate the belief that people with Chagas disease are 
only those migrating from rural or historically endemic 
areas. Additionally, this reinforces the need to accomplish 
the guidelines of universal active screening for Chagas dis-
ease in pregnant women and their infants as well as to imple-
ment the treatment of women of a fertile age to prevent CCD 
transmission [3, 28, 29].
When pursued in the infants’ first months of life, treat-
ment for Chagas disease is safe and effective [2]. The frame-
work for Elimination of Mother-to-Child Transmission of 
HIV, Syphilis, Hepatitis B, and Chagas (EMTCT plus) aims 
to increase treatment to 90% or more infants with CCD [9]. 
However, using the reference standard algorithm, infants 
need to be followed up for a prolonged period until the con-
firmation of a negative or positive serology. In the present 
study, 15% of the patients were lost during the follow-up 
(Fig. 2). This proportion is even higher outside the context 
of reference centers, reaching 55–80% in Argentina [5, 8, 
10]. Thus, better opportunities for early detection and treat-
ment of CCD should be explored in the context of neona-
tal monitoring before the mother-newborn pair has left the 
maternity service (i.e., National Neonatal Screening Pro-
gram in Argentina). Our data show that qPCR is a potential 
tool to achieve the goals of EMTCT plus detecting more 
than 90% of the infected infants in the first analyzed sample 
allowing for the implementation of early treatment. Tak-
ing into account the evidence from this and another recent 
study [30], the algorithm for the diagnosis of CCD should 
be updated to allow qPCR to be used as a tool for early diag-
nosis when supplies and equipment are available.
Although, since 1998, several studies have shown the 
high sensitivity of PCR in CCD diagnosis, in most Latin 
American countries, this tool had not been validated in rou-
tine screening. The diverse arguments placed forward to jus-
tify the limited use of PCR to diagnose CCD include: limited 
evidence that molecular tools perform better than the refer-
ence standard (parasitology at birth and/or serology 8–12 
months after birth), lack of standardization or specificity, 
complexity, and cost [31]. Our present results showed that 
both the sensitivity and specificity of qPCR were 100%, with 
complete agreement with the current diagnostic algorithm 
(Table 1). The results also showed that, even in the context 
of a healthcare center, the available qPCR assay has high 
sensitivity and negative predictive value (NPV), as well as 
high specificity and positive predictive value (PPV) when 
used with appropriate quality controls.
The World Health Organization convened Latin American 
countries to update infant diagnosis practices to ensure early 
and efficient diagnosis and treatment of CCD [9]. There-
fore, early diagnosis of the infection plays an essential role 
in controlling the disease burden in this population. In this 
prospective study, qPCR performed in blood samples from 
infants born to infected mothers was able to detect CCD 
earlier than LAMP and ME (ID: 052, 061, and 101, Table 2). 
For a molecular diagnostic tool to be applied in the first days 
of life, it should be very sensitive because the parasitic loads 
in some patients are low at baseline and increase in the fol-
lowing appointments (Table 2 and Fig. 4). In fact, there is 
evidence that blood sampling at 1 month of life improves the 
sensitivity of diagnosis [27].
Although qPCR is the tool of choice in the most advanced 
microbiology laboratories, it is not always available in low-
resource settings. In a previous analytical study, using this 
LAMP assay targeted to the 18S rRNA genes, we showed 
that the use of colorimetric visualization allows an easy 
judgment of a positive result by the naked eye, allowing 
a rapid detection of results in seven samples selected from 
CCD-infected patients with positive ME [14]. This study 
validates the clinical use of LAMP to detect T. cruzi, show-
ing that this assay would be useful in the detection of CCD. 
LAMP was able to detect infected infants in the first sample 
tested by colorimetric visualization without requiring com-
plex equipment (sensitivity: 69.2%, 95% CI 38.6–90.9 and 
specificity: 100.0%, 95% CI 95.9–100.0).
However, Besuschio et al. tested a LAMP prototype kit, 
so far not commercially available, on a series of archival 
DNA samples from acutely infected patients and found sen-
sitivity and specificity values of 93% and 100%, respectively 
[15, 16]. All the samples they obtained from CCD-infected 
patients (average age 108 days old) yielded positive LAMP 
results and the parasitic loads found were between 5.27 and 
3063.47 par. eq/mL [15, 16]. Because the performance of 
the molecular tests will critically depend on the copy num-
ber of the target sequences, probably, increased sensitivity 
was possible because this prototype kit is targeted to satel-
lite DNA sequences (a higher copy number than the 18S 
rRNA genes). To our knowledge, although another LAMP 
prototype kit exists in Argentina, no results have been pub-
lished on its performance for the diagnosis of CCD. qPCR 
and LAMP assays targeting the same sequence would be 
more appropriate but as these prototype kits are not com-
mercially available, we were limited to evaluating the 18S 
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rRNA-targeted LAMP that had been previously validated 
and could be performed as an in-house assay in the labora-
tory. Future comparative prospective studies must be con-
ducted to determine the clinical validation of these assays.
In this prospective study, LAMP was found to perform 
similarly to ME. Only one sample, with a moderate parasitic 
load, was positive by ME but negative by LAMP (ID: 141, 
320 eq. par./mL, Table 2). Although T. cruzi DTUs in clini-
cal samples were not analyzed, our previous analytical study 
using this LAMP assay was carried out with purified DNA 
from reference T. cruzi strains belonging to the different DTUs 
and showed no significant differences in the analytical sensi-
tivities among them [14]. Technical problems such as DNA 
degradation during storage might have been a possible cause 
for this false-negative LAMP finding. Furthermore, because 
the LAMP assay available for this study did not have IPC and 
we did not have fluorescence reading equipment, a limitation 
of this study is that some low-level LAMP amplification may 
have been missed by the naked eye reading or by a reaction 
inhibition.
In this study, qPCR was more sensitive than LAMP. Nev-
ertheless, although not ideal, this is a simple and practical 
molecular tool that could be performed in healthcare facilities 
without expensive equipment or trained microscopists, provid-
ing results rapidly through detection by the naked eye [31].
In our work, the quality of the qPCR and LAMP assays 
was checked and evaluated continuously by an in-house 
quality-control process. This allowed us to rule out inva-
lid results. In contrast to microscopy, molecular diagnosis 
allows the monitoring of results by a program of quality 
control following the EMTCT plus guidelines  to ensure 
high-quality testing [9].
Molecular diagnostic tools such as those evaluated in 
the present study have numerous advantages, including 
increased sensitivity and specificity and a simpler standardi-
zation of diagnostic procedures. DNA samples can also be 
stored and used for genetic characterization and molecular 
typing, providing a valuable tool for surveys and surveil-
lance studies. The COVID-19 pandemic has proven the 
worth of rapid implementation of molecular diagnostic tools. 
All of these installed capabilities of molecular laboratories 
in the health system should be profited, in the near future, 
for diagnosis of neglected diseases such as Chagas disease.
The study has potential limitations. As Chagas disease has 
a low rate of congenital transmission, the number of infected 
children is small, according to the CIs of the LAMP, in non-
optimal conditions, the sensitivity could be 38.6%, the same 
as an ME (Table 1). In addition, the infants included had 
been referred to the reference center, the youngest being 3 
days old. A recent study in neonates has shown lower sensi-
tivity in neonates studied on the first day of life [30]. These 
limitations could be overcome in multicenter studies that 
allow an evaluation of diagnostic accuracy including neo-
natology services, different operators in the reading of the 
ME, and a greater number of samples.
5  Conclusions
To the best of our knowledge, this is the first study jointly 
reporting the sensitivity, specificity, PPV, and NPV of 
LAMP and qPCR in the diagnosis of CCD. The NPV iden-
tified the limitations of negative LAMP results for ruling out 
infection in non-infected infants; however, high specificity 
and PPV were obtained. As in other studies, the high sensi-
tivity, specificity, PPV, and NPV values highlighted qPCR 
as a valuable tool in the earlier diagnosis of CCD.
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